Drugs / Human Amniotic Membrane
Human Amniotic Membrane
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04130061 | Oct 2019 → Jun 2021 | atrial fibrillation | University of Utah | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05664815 | Sep 2023 → Sep 2025 overdue | osteonecrosis of the jaw | Centre Hospitalier Universitaire de Besancon | Recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00674999 | Jun 2005 → Sep 2008 | — | The University of Texas Medical Branch, Galveston | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Human Amniotic Membrane | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05664815 ↗ |
| Known as | Amnion | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00674999 ↗ |
| Known as | hAM | “The human amniotic membrane (hAM) has poor (even no) immunogenicity and exerts an anti-inflammatory, anti-fibrotic, antimicrobial, antiviral and analgesic effect.” NCT05664815 ↗ |